The effects of antireflux therapy on pulmonary function in patients with severe gastroesophageal reflux disease

S. J. Spechler, D. W. Gordon, J. Cohen, W. O. Williford, W. Krol, D. J. Ahnen, J. Goff, G. Stiegmann, H. Greenlee, T. Schnell, S. J. Sontag, A. T. Kishore, H. Pinkas, R. C. Read, T. R. DeMeester, Stephen J. Lanspa, R. K. Zetterman, C. H. Fredell, S. Levenson

Research output: Contribution to journalArticle

22 Citations (Scopus)

Abstract

Objective: Gastroesophageal reflux can induce bronchospasm, and antireflux therapy has been shown to improve pulmonary function in patients who have gastroesophageal reflux disease (GERD) associated with asthma. Our objective was to study the pulmonary efffects of antireflux therapy in patients who had severe GERD without clinically apparent lung disease. Methods: In a Department of Veterans Affairs Cooperative Study, patients who had complicated GERD without important lung disease were randomly assigned to receive one of three types of antireflux treatment, including two kinds of medical therapy and a surgical therapy. Patients had pulmonary function tests (PFTs), including total lung capacity, residual volume, forced vital capacity, forced expiratory volume in 1 s, maximal midexpiratory flow, and diffusing capacity for carbon monoxide. Results: Two hundred forty-seven patients (243 men, four women; mean age 58 yr) entered the randomized trial, and 151 returned for PFTs at 1 yr. For the entire study group and for all three treatment groups, mean values for PFTs at 1 yr did not differ significantly from those at baseline. Even in subgroups of patients whose baseline PFTs were abnormal and whose esophagitis had healed completely, there were no significant changes in results of PFTs. Conclusions: For veteran patients with severe GERD and no obvious lung disease, 1 yr of antireflux therapy had no important effect on pulmonary function. These findings suggest that GERD is not commonly associated with inapparent, reversible pulmonary dysfunction.

Original languageEnglish
Pages (from-to)915-918
Number of pages4
JournalAmerican Journal of Gastroenterology
Volume90
Issue number6
StatePublished - 1995
Externally publishedYes

Fingerprint

Gastroesophageal Reflux
Respiratory Function Tests
Lung
Lung Diseases
Veterans
Therapeutics
Total Lung Capacity
Bronchial Spasm
Residual Volume
Esophagitis
Vital Capacity
Forced Expiratory Volume
Carbon Monoxide
Asthma

All Science Journal Classification (ASJC) codes

  • Gastroenterology

Cite this

Spechler, S. J., Gordon, D. W., Cohen, J., Williford, W. O., Krol, W., Ahnen, D. J., ... Levenson, S. (1995). The effects of antireflux therapy on pulmonary function in patients with severe gastroesophageal reflux disease. American Journal of Gastroenterology, 90(6), 915-918.

The effects of antireflux therapy on pulmonary function in patients with severe gastroesophageal reflux disease. / Spechler, S. J.; Gordon, D. W.; Cohen, J.; Williford, W. O.; Krol, W.; Ahnen, D. J.; Goff, J.; Stiegmann, G.; Greenlee, H.; Schnell, T.; Sontag, S. J.; Kishore, A. T.; Pinkas, H.; Read, R. C.; DeMeester, T. R.; Lanspa, Stephen J.; Zetterman, R. K.; Fredell, C. H.; Levenson, S.

In: American Journal of Gastroenterology, Vol. 90, No. 6, 1995, p. 915-918.

Research output: Contribution to journalArticle

Spechler, SJ, Gordon, DW, Cohen, J, Williford, WO, Krol, W, Ahnen, DJ, Goff, J, Stiegmann, G, Greenlee, H, Schnell, T, Sontag, SJ, Kishore, AT, Pinkas, H, Read, RC, DeMeester, TR, Lanspa, SJ, Zetterman, RK, Fredell, CH & Levenson, S 1995, 'The effects of antireflux therapy on pulmonary function in patients with severe gastroesophageal reflux disease', American Journal of Gastroenterology, vol. 90, no. 6, pp. 915-918.
Spechler, S. J. ; Gordon, D. W. ; Cohen, J. ; Williford, W. O. ; Krol, W. ; Ahnen, D. J. ; Goff, J. ; Stiegmann, G. ; Greenlee, H. ; Schnell, T. ; Sontag, S. J. ; Kishore, A. T. ; Pinkas, H. ; Read, R. C. ; DeMeester, T. R. ; Lanspa, Stephen J. ; Zetterman, R. K. ; Fredell, C. H. ; Levenson, S. / The effects of antireflux therapy on pulmonary function in patients with severe gastroesophageal reflux disease. In: American Journal of Gastroenterology. 1995 ; Vol. 90, No. 6. pp. 915-918.
@article{9ffd58208a804f1288b0612330eff221,
title = "The effects of antireflux therapy on pulmonary function in patients with severe gastroesophageal reflux disease",
abstract = "Objective: Gastroesophageal reflux can induce bronchospasm, and antireflux therapy has been shown to improve pulmonary function in patients who have gastroesophageal reflux disease (GERD) associated with asthma. Our objective was to study the pulmonary efffects of antireflux therapy in patients who had severe GERD without clinically apparent lung disease. Methods: In a Department of Veterans Affairs Cooperative Study, patients who had complicated GERD without important lung disease were randomly assigned to receive one of three types of antireflux treatment, including two kinds of medical therapy and a surgical therapy. Patients had pulmonary function tests (PFTs), including total lung capacity, residual volume, forced vital capacity, forced expiratory volume in 1 s, maximal midexpiratory flow, and diffusing capacity for carbon monoxide. Results: Two hundred forty-seven patients (243 men, four women; mean age 58 yr) entered the randomized trial, and 151 returned for PFTs at 1 yr. For the entire study group and for all three treatment groups, mean values for PFTs at 1 yr did not differ significantly from those at baseline. Even in subgroups of patients whose baseline PFTs were abnormal and whose esophagitis had healed completely, there were no significant changes in results of PFTs. Conclusions: For veteran patients with severe GERD and no obvious lung disease, 1 yr of antireflux therapy had no important effect on pulmonary function. These findings suggest that GERD is not commonly associated with inapparent, reversible pulmonary dysfunction.",
author = "Spechler, {S. J.} and Gordon, {D. W.} and J. Cohen and Williford, {W. O.} and W. Krol and Ahnen, {D. J.} and J. Goff and G. Stiegmann and H. Greenlee and T. Schnell and Sontag, {S. J.} and Kishore, {A. T.} and H. Pinkas and Read, {R. C.} and DeMeester, {T. R.} and Lanspa, {Stephen J.} and Zetterman, {R. K.} and Fredell, {C. H.} and S. Levenson",
year = "1995",
language = "English",
volume = "90",
pages = "915--918",
journal = "American Journal of Gastroenterology",
issn = "0002-9270",
publisher = "Nature Publishing Group",
number = "6",

}

TY - JOUR

T1 - The effects of antireflux therapy on pulmonary function in patients with severe gastroesophageal reflux disease

AU - Spechler, S. J.

AU - Gordon, D. W.

AU - Cohen, J.

AU - Williford, W. O.

AU - Krol, W.

AU - Ahnen, D. J.

AU - Goff, J.

AU - Stiegmann, G.

AU - Greenlee, H.

AU - Schnell, T.

AU - Sontag, S. J.

AU - Kishore, A. T.

AU - Pinkas, H.

AU - Read, R. C.

AU - DeMeester, T. R.

AU - Lanspa, Stephen J.

AU - Zetterman, R. K.

AU - Fredell, C. H.

AU - Levenson, S.

PY - 1995

Y1 - 1995

N2 - Objective: Gastroesophageal reflux can induce bronchospasm, and antireflux therapy has been shown to improve pulmonary function in patients who have gastroesophageal reflux disease (GERD) associated with asthma. Our objective was to study the pulmonary efffects of antireflux therapy in patients who had severe GERD without clinically apparent lung disease. Methods: In a Department of Veterans Affairs Cooperative Study, patients who had complicated GERD without important lung disease were randomly assigned to receive one of three types of antireflux treatment, including two kinds of medical therapy and a surgical therapy. Patients had pulmonary function tests (PFTs), including total lung capacity, residual volume, forced vital capacity, forced expiratory volume in 1 s, maximal midexpiratory flow, and diffusing capacity for carbon monoxide. Results: Two hundred forty-seven patients (243 men, four women; mean age 58 yr) entered the randomized trial, and 151 returned for PFTs at 1 yr. For the entire study group and for all three treatment groups, mean values for PFTs at 1 yr did not differ significantly from those at baseline. Even in subgroups of patients whose baseline PFTs were abnormal and whose esophagitis had healed completely, there were no significant changes in results of PFTs. Conclusions: For veteran patients with severe GERD and no obvious lung disease, 1 yr of antireflux therapy had no important effect on pulmonary function. These findings suggest that GERD is not commonly associated with inapparent, reversible pulmonary dysfunction.

AB - Objective: Gastroesophageal reflux can induce bronchospasm, and antireflux therapy has been shown to improve pulmonary function in patients who have gastroesophageal reflux disease (GERD) associated with asthma. Our objective was to study the pulmonary efffects of antireflux therapy in patients who had severe GERD without clinically apparent lung disease. Methods: In a Department of Veterans Affairs Cooperative Study, patients who had complicated GERD without important lung disease were randomly assigned to receive one of three types of antireflux treatment, including two kinds of medical therapy and a surgical therapy. Patients had pulmonary function tests (PFTs), including total lung capacity, residual volume, forced vital capacity, forced expiratory volume in 1 s, maximal midexpiratory flow, and diffusing capacity for carbon monoxide. Results: Two hundred forty-seven patients (243 men, four women; mean age 58 yr) entered the randomized trial, and 151 returned for PFTs at 1 yr. For the entire study group and for all three treatment groups, mean values for PFTs at 1 yr did not differ significantly from those at baseline. Even in subgroups of patients whose baseline PFTs were abnormal and whose esophagitis had healed completely, there were no significant changes in results of PFTs. Conclusions: For veteran patients with severe GERD and no obvious lung disease, 1 yr of antireflux therapy had no important effect on pulmonary function. These findings suggest that GERD is not commonly associated with inapparent, reversible pulmonary dysfunction.

UR - http://www.scopus.com/inward/record.url?scp=0028997646&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028997646&partnerID=8YFLogxK

M3 - Article

C2 - 7771420

AN - SCOPUS:0028997646

VL - 90

SP - 915

EP - 918

JO - American Journal of Gastroenterology

JF - American Journal of Gastroenterology

SN - 0002-9270

IS - 6

ER -